Americas
23 April 2026 The US pharma giant is spending up to $1 billion to build an end-to-end biosimilar platform and is counting on a decade of expiring biologic patents to make it pay off.
22 April 2026
20 April 2026
17 April 2026
Latest Features
Americas
From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.
Europe
Traceability and transparency of training practices, and the value of bespoke tool, are among the key AI trends that will be shaped by legal and regulatory developments in 2026, write experts from Rouse.
Americas
Companies that integrate data rights into their IP strategy with a holistic approach will lead in innovation while minimising risk, says Terri Shieh-Newton of Mintz.
Americas
In the complex world of bsAb patenting, counsel need to turn chefs to serve up success. Benjamin Pelletier of Haynes Boone puts together a menu of dos and don’ts.
Americas
The USPTO’s ‘settled expectations’ rule is anything but settled, argues Andrew Zappia of Troutman Pepper Locke.
Americas
In the second of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax delve into the real reasons why medicine costs more in the US.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones.
More News
15 April 2026 The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.
14 April 2026 A US district court has allowed key elements of the generic drugmaker’s case against a rival to move forward, while drawing clear limits on how far the complaint can reach.
13 April 2026 The US tech company targets a disgruntled ex-employee for threatening to sell its trade secrets if he does not receive an “unreasonable fee”.
10 April 2026 The 2026 panel has been chosen. With judges from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron and law firms such as White & Case and Arnold & Porter, here’s who will be deciding this year’s winners.
9 April 2026 The firm has added two partners to its government and regulatory team, bringing expertise in FDA matters, product approvals, and regulatory risk.
8 April 2026 The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
7 April 2026 On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox